^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Cancer
    Drug:5-fluorouracil (Thymidylate synthase inhibitor) +
    Onivyde (nanoliposomal irinotecan) (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Metastatic Pancreatic Cancer: ASCO Guideline Update

    Published date:
    08/05/2020
    Excerpt:
    Recommendations…Treatment Options After First-Line Therapy…Fluorouracil plus nanoliposomal irinotecan, or fluorouracil plus irinotecan where the former combination is unavailable, is preferred as a second-line therapy…
    DOI:
    10.1200/JCO.20.01364 Journal of Clinical Oncology